Insulin medication(s)-Lantus (Glargine) Posts on Medivizor
Navigation Menu

Insulin medication(s)-Lantus (Glargine) Posts on Medivizor

Can iGlarLixi improve blood glucose control in patients receiving basal insulin?

Can iGlarLixi improve blood glucose control in patients receiving basal insulin?

Posted by on May 24, 2020 in Diabetes mellitus | 0 comments

In a nutshell This study looked at whether iGlarLixi (Soliqua), a combination of long-acting insulin glargine (Lantus) and lixisenatide (Lyxumia), can improve glucose control for patients with type 2 diabetes (T2D) uncontrolled with long-acting insulin alone. It found that iGlarLixi improved overall and after-meal blood sugar control compared to insulin...

Read More

Efficacy and safety of insulin glargine 300 units/mL vs insulin glargine 100 units/mL in adult patients with type 1 diabetes

Posted by on May 29, 2019 in Diabetes mellitus | 0 comments

In a nutshell This article compared the safety and effectiveness of insulin glargine (Lantus) at two different doses in the management of type 1 diabetes (T1D). The authors concluded that the effectiveness and safety of both doses were similar.  Some background In T1D the body does not make insulin and cannot lower the blood...

Read More

Looking for patients with type 2 diabetes treated with basal insulin to try a new investigational drug

Posted by on Feb 13, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study is examining the safety and effectiveness of a new insulin plan for people with type 2 diabetes (T2D) that are already being treated with basal insulin. The new insulin being evaluated is a once-a-week administration of insulin instead of daily injections of basal insulin, which should be substantially more convenient for...

Read More

Does IDegLira improve outcomes in patients with uncontrolled type 2 diabetes?

Posted by on Aug 8, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the effects of IDegLira, a combination insulin drug, on outcomes in patients with uncontrolled type 2 diabetes. They found that IDegLira improved glycemic (blood sugar) control and aided weight loss in these patients. Some background The treatment of type 2 diabetes is to achieve glycemic control. This can slow...

Read More

Continuous glucose monitoring improves glycemic control in patients with type 1 diabetes

Posted by on Jul 15, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the effect of continuous glucose monitoring (CGM) in managing blood sugar levels in patients with type 1 diabetes treated with multiple daily insulin injections. They found CGM resulted in a clinically meaningful improvement in glycemic (blood sugar) control. Some background Glycemic control is critical for...

Read More

Insulin degludec vs. insulin glargine: which one gives more consistent blood glucose levels?

Posted by on Jun 22, 2015 in Diabetes mellitus | 0 comments

In a nutshell This study examined the variability of insulin degludec and insulin glargine in reducing blood glucose levels. Some background Patients with type1 diabetes (T1D) must inject rapid-acting insulin and long-acting insulin each day. Insulin glargine (Lantus) is a long-acting insulin injected once daily. It slowly reduces blood glucose...

Read More

Insulin degludec results in a higher quality of life compared to insulin glargine

Posted by on Aug 14, 2013 in Diabetes mellitus | 0 comments

In a nutshell In this study researchers examined two types of insulin; insulin degludec (triseba; IDeg) and insulin glargine (lantus; IGlar). This study compared the quality of life (QOL) as reported by patients between users of these two drugs. Some background Insulin is often used to manage blood sugar levels in diabetic patients. However,...

Read More